Resorbable Magnesium Scaffolds Registry

RecruitingOBSERVATIONAL
Enrollment

1,106

Participants

Timeline

Start Date

November 18, 2020

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2026

Conditions
Coronary Artery Disease
Interventions
DEVICE

Magmaris

MAGMARIS is indicated for improving luminal diameter in the treatment of de novo native coronary artery lesions in patients with symptomatic coronary artery disease. The reference vessel diameter should closely match the scaffold nominal diameter. The treated lesion length should be less than the nominal scaffold length.

Trial Locations (2)

23795

RECRUITING

Heart Center Segeberger Kliniken, Bad Segeberg

Unknown

RECRUITING

Herz-und Gefäßzentrum Oberallgäu-Kempten, Kempten

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biotronik AG

INDUSTRY

NCT04679740 - Resorbable Magnesium Scaffolds Registry | Biotech Hunter | Biotech Hunter